Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, double-blind, randomised-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR (TM)) as monotherapy in the maintenance treatment of patients with major depressive disorder.

Next Previous
Trial Profile

A multi-centre, double-blind, randomised-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR (TM)) as monotherapy in the maintenance treatment of patients with major depressive disorder.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms AMETHYST
  • Sponsors AstraZeneca

    • Most Recent Events

    • 31 Jul 2012 Results published in the International Clinical Psychopharmacology.
    • 16 Sep 2009 Results of a secondary analysis investigating the effects of quetiapine on functioning and sleep quality have been presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology.
    • 03 May 2008 Results have been presented at the 161st Annual Meeting of the American Psychiatric Association.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top